Development of a novel-ionizable-lipid-based mRNA vaccine for broad protection against <i>Streptococcus pneumoniae</i>.

ABSTRACT: Recently, messenger RNA (mRNA)-based vaccine technology has made significant advances in preventing pathogenic microbial infections. The composition and physicochemical properties of lipid nanoparticle (LNP) determine the delivery efficiency of mRNA vaccines. In this study, we synthesized a novel ionizable lipid, C14-192, featuring a 3-oxo-polyamine head group, which was used as a component for LNP to encapsulate and deliver mRNA. Analysis of in vitro and in vivo expression showed that C14-192-LNP-encapsulated luciferase mRNA exhibited high expression efficiency. To further assess the potential of the C14-192 LNP formulation for vaccine applications, we developed a prophylactic mRNA vaccine against Streptococcus pneumoniae (S. pneumoniae), based on the conserved

SUBMITTER: Xu S 

PROVIDER: S-EPMC12744836 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature